Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

Anne Monks Ph.D. [Contractor]

SAIC-Frederick Inc.
Frederick National Laboratory for Cancer Research
Building 432, Room 232
Frederick, MD 21702-1201
Phone: 301-886-5528
Email: monksa@mail.nih.gov

Functional Genomics Laboratory

The Functional Genomics Laboratory provides genomic techniques, including gene expression microarrays, exon arrays, microRNA arrays, TaqMan® real-time polymerase chain reaction (RT-PCR), reporter gene assays, multiplexing gene assays, RNA interference, methylation assays, metabolic analyses and others as tools to identify potential drug targets and to determine the role of selected genes in the mechanisms of drug action and cellular responses to stressors. These methods are useful to probe for insights into the mechanisms of action of novel agents, as well as for detailed analyses of specific cells. The functional genomics lab is a resource that is widely tapped into by collaborators within NCI as well as external investigators. The FGL has taken on large-scale projects including profiling of gene expression changes in the NCI60 cell line panel following exposure to 15 anticancer agents with varied mechanisms of action after 2, 6 and 24 hours exposure at two concentrations. Analyses of these data may elucidate cellular responses to the drugs and potentially lead to new rationale drug combinations or elucidate new points of vulnerability in the malignant cells which can be targeted with therapeutic agents. FGL is currently involved in the full genomic characterization (gene expression, exon expression, mutations, deletions, amplifications, microRNAs and other non-coding RNAs) of the human sarcoma lines and SCLC lines with a goal of identifying potential drug targets in normal and mutant proteins.

Credentials

Dr. Anne Monks was educated in Great Britain and received her honors degree in Applied Biology from Hatfield University in 1975. She studied for her Ph.D. at the Clinical Pharmacology Department of St. Bartholomews Hospital and was awarded the degree in Clinical Pharmacology from London University in 1979. Dr. Monks became a Fogarty Fellow from 1979-1982 in the Laboratory of Chemical Pharmacology, DTP, NCI, then became a Visiting Associate in the same laboratory until 1985. During her tenure at NIH she investigated the homeostatic control of circulating nucleosides and their effect on clinical antimetabolites using the rat liver perfusion model. In 1995, Dr. Monks joined the NCI-Frederick Cancer and Research Facility as a contractor (currently SAIC-Frederick, http://www.saic.com/) dedicated to support the Developmental Therapeutics Program's newly proposed ‘In Vitro Anti-Cancer Drug Screening Program.’ Her group’s current research is directed towards measuring and understanding how gene expression changes in response to drug treatment, in cell lines with different genetic backgrounds, can enhance g the mechanism of response of cell lines and by extension, tumors, to these drugs. Moreover, in concert with the mission of the MPB, they play an important role in characterizing the genomics of rare and neglected cancers to provide a resource for DCTD and the scientific community to have an opportunity to improve therapeutics in these areas.

Recent Publications

  1. N. D. Fer, R. H. Shoemaker, A. Monks, Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. J. Exp. Clin. Cancer Res. 29, 91 (2010).
  2. A. G. Jobson et al., Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp. Ther. 331, 816 (Dec, 2009).
  3. T. Kosakowska-Cholody et al., Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. Cancer Chemother. Pharmacol. 63, 769 (Apr, 2009).
  4. S. Kummar et al., Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27, 2705 (Jun 1, 2009).
  5. A. Monks et al., Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer. Drugs 20, 682 (Sep, 2009).
  6. U. Muus et al., Development of antiproliferative phenylmaleimides that activate the unfolded protein response. Bioorg. Med. Chem. 18, 4535 (Jun 15, 2010).
  7. V. Saini et al., Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS ONE 7, e41401 (2012).
  8. G. Zoppoli et al., CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene 31, 403 (Jan 26, 2012).

About the Branch Chief

Dr. Mary K. Wolpert, Ph.D. Dr. Beverly A. Teicher PhD is Chief of the Molecular Pharmaco-logy Branch at NCI, a position that she assumed in early 2011. One focus of the Molecular Pharmacology Branch is target and drug discovery for rare and recalcitrant cancers such as sarcoma and small cell lung cancer. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. More…